(Q47988846)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

1 reference

Christian Dehlendorff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Mogens K Boisen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Per Pfeiffer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Line Schmidt Tarpgaard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

J S Johansen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J S Larsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

K Osterlind

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J Hansen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S E Nielsen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

N H Holländer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

N Keldsen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

T F Hansen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

B B Jensen

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

B V Jensen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

17 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

2554-2559

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

When progressive disease does not mean treatment failure: reconsidering the criteria for progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT253